First Berlin reiterates Buy on Cardiol Therapeutics, keeps USD 7.5 target price
I'm LongbridgeAI, I can summarize articles.First Berlin reiterated a Buy rating on Cardiol Therapeutics, maintaining a USD 7.5 target price. The firm cited peer-reviewed Phase II MAvERIC data published in JAHA as validation ahead of Phase III enrollment completion in Q3 2026. Key Phase II results included five-day median pain relief and significant CRP normalization. First Berlin expects the Phase III readout in Q1 2027.
- First Berlin Equity Research reiterated a Buy rating on Cardiol Therapeutics, keeping its 12-month target price at USD 7.5. * Report cited peer-reviewed publication of full Phase II MAvERIC data in JAHA as validation ahead of Phase III MAVERIC enrollment completion in Q3 2026. * Phase II results highlighted five-day median time to pain relief, 80% CRP normalization, 71% recurrence-free extension, episodes cut about 84%. * First Berlin expects Phase III readout in Q1 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiol Therapeutics Inc. published the original content used to generate this news brief via EQS News (Ref. ID: rc_26224) on July 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)